A simple index of lipid overaccumulation is a good marker of liver steatosis
- PMID: 20738844
- PMCID: PMC2940930
- DOI: 10.1186/1471-230X-10-98
A simple index of lipid overaccumulation is a good marker of liver steatosis
Abstract
Background: Liver steatosis is often found in association with common cardiometabolic disorders, conditions that may all occur in a shared context of abdominal obesity and dyslipidemia. An algorithm for identifying liver steatosis is the fatty liver index (FLI). The lipid accumulation product (LAP) is an index formulated in a representative sample of the US population to identify cardiometabolic disorders. Because FLI and LAP share two components, namely waist circumference and fasting triglycerides, we evaluated the ability of LAP to identify liver steatosis in the same study population from the Northern Italian town where FLI was initially developed.
Methods: We studied 588 individuals (59% males) aged 21 to 79 years. Liver steatosis was detected by ultrasonography and coded ordinally as none, intermediate and severe. 44% of the individuals had liver steatosis. Using proportional-odds ordinal logistic regression, we evaluated the ability of log-transformed LAP (lnLAP) to identify liver steatosis. We considered the benefits to our model of including terms for sex, age, suspected liver disease and ethanol intake. We calculated the 3-level probability of liver steatosis according to lnLAP and sex, providing tables and nomograms for risk assessment.
Results: An ordinal proportional-odds model consisting of lnLAP and sex offered a reasonably accurate identification of liver steatosis. The odds of more severe vs. less severe steatosis increased for increasing values of lnLAP (odds ratio [OR] = 4.28, 95%CI 3.28 to 5.58 for each log-unit increment) and was more likely among males (OR = 1.88, 95%CI 1.31 to 2.69).
Conclusion: In a study sample of adults from Northern Italy, the simple calculation of LAP was a reasonably accurate approach to recognizing individuals with ultrasonographic liver steatosis. LAP may help primary care physicians to select subjects for liver ultrasonography and intensified lifestyle counseling, and researchers to select patients for epidemiologic studies. A more thorough assessment of LAP's potential for identifying liver steatosis will require its cross-evaluation in external populations.
Figures
Similar articles
-
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.BMC Gastroenterol. 2006 Nov 2;6:33. doi: 10.1186/1471-230X-6-33. BMC Gastroenterol. 2006. PMID: 17081293 Free PMC article.
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.Ann Hepatol. 2013 Jan-Feb;12(1):70-7. Ann Hepatol. 2013. PMID: 23293196
-
Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study.Metab Syndr Relat Disord. 2013 Dec;11(6):412-6. doi: 10.1089/met.2012.0147. Epub 2013 Jul 31. Metab Syndr Relat Disord. 2013. PMID: 23902132
-
External validation of the fatty liver index and lipid accumulation product indices, using 1H-magnetic resonance spectroscopy, to identify hepatic steatosis in healthy controls and obese, insulin-resistant individuals.Eur J Endocrinol. 2014 Nov;171(5):561-9. doi: 10.1530/EJE-14-0112. Eur J Endocrinol. 2014. PMID: 25298375
-
The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison.BMC Cardiovasc Disord. 2005 Sep 8;5:26. doi: 10.1186/1471-2261-5-26. BMC Cardiovasc Disord. 2005. PMID: 16150143 Free PMC article.
Cited by
-
Hepatic steatosis index and lipid accumulation product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study.Intern Emerg Med. 2013 Apr;8(3):265-7. doi: 10.1007/s11739-012-0875-9. Epub 2012 Nov 25. Intern Emerg Med. 2013. PMID: 23184441 No abstract available.
-
Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD) after Liver Transplantation: A Narrative Review of an Emerging Issue.J Clin Med. 2024 Jun 30;13(13):3871. doi: 10.3390/jcm13133871. J Clin Med. 2024. PMID: 38999436 Free PMC article. Review.
-
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.Ther Adv Endocrinol Metab. 2022 Dec 10;13:20420188221139650. doi: 10.1177/20420188221139650. eCollection 2022. Ther Adv Endocrinol Metab. 2022. PMID: 36533185 Free PMC article. Review.
-
Could Inflammatory Indices and Metabolic Syndrome Predict the Risk of Cancer Development? Analysis from the Bagnacavallo Population Study.J Clin Med. 2020 Apr 20;9(4):1177. doi: 10.3390/jcm9041177. J Clin Med. 2020. PMID: 32325965 Free PMC article.
-
Anthropometric and blood parameters for the prediction of NAFLD among overweight and obese adults.BMC Gastroenterol. 2018 Jul 13;18(1):113. doi: 10.1186/s12876-018-0840-9. BMC Gastroenterol. 2018. PMID: 30005625 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials